Since the RAS/mitogen-activated protein kinase (MAPK) pathway regulates multiple important biological processes such as cell proliferation, migration and survival, and p90RSK is overactivated in many human tumors such as lung cancer, breast cancer and prostate cancer, in recent years, the possibility has emerged of considering p90RSK an excellent target in anti-tumor therapy. This evidence concerns the gene RPS6KA1 and prostate carcinoma.